Single Ascending Dose Study of NRS 033 in Healthy Volunteers

Phase 1 Completed 24 enrolled Nirsum Labs National Institute on Drug Abuse (NIDA) · collab

RandomizedSequentialDouble-blindTreatment

Summary

This is a phase 1, first in human, randomized, double-blind, placebo-controlled, single ascending dose (SAD) study in healthy adult male and female subjects 18 to 55 years of age, inclusive.

Timeline

Start: 2023-04-17
Primary completion: 2024-12-04
Completion: 2024-12-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NRS-033	Unknown	—	—

Indications

No indication recorded.